Background: Induced Pluripotent Stem Cell (IPSC) Technology is the most advanced
research as it offers an attractive alternative for establishing patient-specific IPSCs
to recapitulate phenotypes of not only monogenic diseases (viz. Thalassaemia, Sickle cell
anemia, Haemophilia, Tay-Sachs disease), but also late-onset polygenic diseases (viz. Parkinson's
disease, Alzheimer's disease, schizophrenia). Over the hindsight, numerous studies
of the past and current scientists have led to the production, maturation and understanding
of induced pluripotent stem cell technology and its use in basic and clinical research.
Methods: A systematic search of peer-reviewed scientific literature and clinical trials in
public databases were carried out to summarize the evidence on the use of IPSC.
Results: Current review sheds light upon the use of patient-derived iPSC models in drug
toxicity, screening and discovery which have been derived after referring to more than 200
articles in literature. Furthermore, their use as disease models was also studied signifying
the versatility of iPSC lines.
Conclusion: Through this review, we describe the advent of iPSC technology, where we
comprehensively cover the generation of iPSCs and their characterization along with their
prospective applications using IPSC banks in disease modeling and drug screening.